Fanapt Sanctioned for Schizophrenia
But FDA warns against off-label use
Posted May 7, 2009
THURSDAY, May 7 (HealthDay News) -- A new pill to treat adults with schizophrenia has been approved by the U.S. Food and Drug Administration.
Fanapt (iloperidone), which belongs to the atypical antipsychotic class of drugs, is not approved for patients with dementia-related psychosis, United Press International reported.
The FDA ordered that Fanapt carry a boxed warning about the increased risk of death associated with off-label use of the drug to treat behavioral problems in patients with dementia-related psychosis.
Fanapt is made by Patheon Inc., in Ontario, Canada, for Vanda Pharmaceuticals Inc., of Rockville, Md., UPI reported.
More information
The FDA has more about this approval.
advertisement
